BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Obesity readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Obesity\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06662383-118@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:retatrutide: Phase 3 readout est. (NCT06662383)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesit
 y\nEstimated primary completion: November 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06662383
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914895-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06914895)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabet
 es and Obesity or Overweight\nEstimated primary completion: November 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 14895
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962280-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06962280)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Long-Term
  Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesi
 ty or Overweight\nEstimated primary completion: November 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06962280
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577090-251@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:nimacimab: Phase 2 readout est. (NCT06577090)
DESCRIPTION:nimacimab\, phase 2\, Obesity.\nStudy: Study to Evaluate the Ef
 fect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Sema
 glutide vs Placebo\nEstimated primary completion: 20 November 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nimacimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06577090
URL:https://assetmemo.bio/drug/nimacimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820099-186@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Safiglipron (HRS-7535): Phase 2 readout est. (NCT06820099)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 2\, Obesity.\nStudy: Study on th
 e Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejecti
 on Fraction/Preserved Ejection Fraction Heart Failure and Obesity\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06820099
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994650-185@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ribupatide: Phase 3 readout est. (NCT06994650)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Multicenter\, Randomi
 zed\, Double-blind\, Placebo-controlled Phase III Clinical Study to Evalua
 te the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructi
 ve Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Venti
 lation (PAP) Therapy\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06994650
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974851-185@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ribupatide: Phase 3 readout est. (NCT06974851)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Phase III Study Evalu
 ating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstru
 ctive Sleep Apnea (OSA) and Obesity\nEstimated primary completion: Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069748
 51
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230132-205@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:ZT006: Phase 2 readout est. (NCT07230132)
DESCRIPTION:ZT006\, phase 2\, Obesity.\nStudy: Efficacy and Safety of ZT006
  in Overweight and Obese Participants\nEstimated primary completion: 12 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zt006#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072301
 32
URL:https://assetmemo.bio/drug/zt006#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184632-138@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:NNC0662-0419: Phase 2 readout est. (NCT07184632)
DESCRIPTION:NNC0662-0419\, phase 2\, Obesity.\nStudy: A Research Study on H
 ow Well Different Doses of the Medicine NNC0662-0419 Help People Living Wi
 th Overweight or Obesity\nEstimated primary completion: 14 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nnc0662-0419#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07184632
URL:https://assetmemo.bio/drug/nnc0662-0419#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06802081-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06802081)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: TIRzepatide
  for the Treatment of Obesity in Patients With Atrial Fibrillation\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06802081
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05173714-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT05173714)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Sit Less\, In
 teract and Move More (SLIMM) 2 Study\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semagluti
 de-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05173714
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06884293-183@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:mazdutide: Phase 3 readout est. (NCT06884293)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study Comparing IBI362
  vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfu
 nction-associated Fatty Liver Disease （MAFLD）\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/mazdutide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06884293
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205900-232@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:HM15275: Phase 2 readout est. (NCT07205900)
DESCRIPTION:HM15275\, phase 2\, Obesity.\nStudy: Study to Evaluate HM15275 
 in Obese or Overweight Subjects Without Diabetes Mellitus\nEstimated prima
 ry completion: January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/hm15275#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07205900
URL:https://assetmemo.bio/drug/hm15275#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243171-268@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270105
DTEND;VALUE=DATE:20270106
SUMMARY:Ecnoglutide (VRB-101): Phase 1/2 readout est. (NCT07243171)
DESCRIPTION:Ecnoglutide (VRB-101)\, phase 1/2\, Obesity.\nStudy: A Phase Ib
 /IIa Study to Evaluate the Safety\, Tolerability\, Pharmacokinetics and Ph
 armacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Ov
 erweight or Obesity\nEstimated primary completion: 5 January 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ecnoglutide-vrb-101#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07243171
URL:https://assetmemo.bio/drug/ecnoglutide-vrb-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395687-199@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:UBT251: Phase 2 readout est. (NCT07395687)
DESCRIPTION:UBT251\, phase 2\, Obesity.\nStudy: A Research Study on How Wel
 l Different Doses of the Medicine UBT251 Help People Living With Overweigh
 t or Obesity\nEstimated primary completion: 14 January 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07395687
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858839-143@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT068588
 39)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 
 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nEstimated primary 
 completion: 21 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06858839
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858878-143@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT068588
 78)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With
  Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nEstimated pr
 imary completion: 21 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06858878
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06151964-149@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Lenbelintide: Phase 1/2 readout est. (NCT06151964)
DESCRIPTION:Lenbelintide\, phase 1/2\, Obesity.\nStudy: A Trial to Learn Ho
 w Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or 
 Without Type 2 Diabetes Who Are Living With Obesity and Overweight\nEstima
 ted primary completion: 29 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/lenbelintide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06151964
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06151964-150@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:AZD9550: Phase 1/2 readout est. (NCT06151964)
DESCRIPTION:AZD9550\, phase 1/2\, Obesity.\nStudy: A Trial to Learn How Saf
 e AZD9550 Monotherapy and Combined With AZD6234 is in People With or Witho
 ut Type 2 Diabetes Who Are Living With Obesity and Overweight\nEstimated p
 rimary completion: 29 January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/azd9550#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06151964
URL:https://assetmemo.bio/drug/azd9550#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07009171-730@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tisolagiline: Phase 2 readout est. (NCT07009171)
DESCRIPTION:Tisolagiline\, phase 2\, Obesity.\nStudy: Study to Evaluate the
  Efficacy and Safety of KDS2010 in Overweight or Obese Patients\nEstimated
  primary completion: 31 January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tisolagiline#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07009171
URL:https://assetmemo.bio/drug/tisolagiline#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937203-173@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ARO-ALK7: Phase 1/2 readout est. (NCT06937203)
DESCRIPTION:ARO-ALK7\, phase 1/2\, Obesity.\nStudy: A First-In-Human Study 
 of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellit
 us\nEstimated primary completion: February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/aro-alk7#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06937203
URL:https://assetmemo.bio/drug/aro-alk7#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724340-213@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:AT-7687: Phase 2 readout est. (NCT07724340)
DESCRIPTION:AT-7687\, phase 2\, Obesity.\nStudy: A Study to Assess the Effi
 cacy\, Safety and Tolerability of AT673 Co-administered With Semaglutide i
 n Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity\
 nEstimated primary completion: February 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/at-7687#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07724340
URL:https://assetmemo.bio/drug/at-7687#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672549-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06672549)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Platform
  Trial for Pediatric Participants With Obesity or Overweight (LY900040)\nE
 stimated primary completion: February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/orforglipron#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06672549
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07521631-196@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:HDM1005: Phase 2 readout est. (NCT07521631)
DESCRIPTION:HDM1005\, phase 2\, Obesity.\nStudy: Efficacy and Safety of HDM
 1005 Compared to Tirzepatide in Obese Adults Without Diabetes\nEstimated p
 rimary completion: 4 February 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hdm1005#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07521631
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07481747-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07481747)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Efficacy an
 d Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are
  Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
 \nEstimated primary completion: 14 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07481747
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073417-193@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270227
DTEND;VALUE=DATE:20270228
SUMMARY:ecnoglutide: Phase 2 readout est. (NCT07073417)
DESCRIPTION:ecnoglutide\, phase 2\, Obesity.\nStudy: A Study to Compare XW0
 03 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLI
 MMER-UP-SWITCH)\nEstimated primary completion: 27 February 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ecnoglutide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07073417
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07658560-200@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:BGM0504: Phase 2 readout est. (NCT07658560)
DESCRIPTION:BGM0504\, phase 2\, Obesity.\nStudy: A Study to Evaluate Effica
 cy and Safety of BGM0504 Tablets in Overweight or Obese Participants Witho
 ut Diabetes\nEstimated primary completion: 28 February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bgm0504#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07658560
URL:https://assetmemo.bio/drug/bgm0504#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215559-245@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:macupatide: Phase 2 readout est. (NCT07215559)
DESCRIPTION:macupatide\, phase 2\, Obesity.\nStudy: A Study of Macupatide (
 LY3532226) and Eloralintide (LY3841136)\, Alone or in Combination\, in Adu
 lts With Obesity or Overweight and With Type 2 Diabetes\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/macupatide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07215559
URL:https://assetmemo.bio/drug/macupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215559-278@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:eloralintide: Phase 2 readout est. (NCT07215559)
DESCRIPTION:eloralintide\, phase 2\, Obesity.\nStudy: A Study of Macupatide
  (LY3532226) and Eloralintide (LY3841136)\, Alone or in Combination\, in A
 dults With Obesity or Overweight and With Type 2 Diabetes\nEstimated prima
 ry completion: March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/eloralintide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07215559
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07690826-187@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HRS-4729: Phase 2 readout est. (NCT07690826)
DESCRIPTION:HRS-4729\, phase 2\, Obesity.\nStudy: A Study to Evaluate the E
 fficacy and Safety of HRS-4729 Injection in Obesity\nEstimated primary com
 pletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 hrs-4729#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07690826
URL:https://assetmemo.bio/drug/hrs-4729#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101939-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07101939)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: A Study of th
 e Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in O
 bese Patents During (PROACT 1)\, and Post-semaglutide Therapy (PROACT 2)\n
 Estimated primary completion: March 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07101939
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285902-185@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ribupatide: Phase 3 readout est. (NCT07285902)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Study Comparing the E
 fficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subj
 ects With Obesity\nEstimated primary completion: March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07285902
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011667-121@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0701
 1667)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Look at How Well CagriSema Helps People Living With
  Obesity Lose Weight and Maintain Weight Loss in the Long-term\nEstimated 
 primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cagrilintide-semaglutide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07011667
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760546-123@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270313
DTEND;VALUE=DATE:20270314
SUMMARY:Imcivree (setmelanotide): Phase 3 readout est. (NCT06760546)
DESCRIPTION:Imcivree (setmelanotide)\, phase 3\, Obesity.\nStudy: A Trial o
 f Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-stud
 y of NCT05774756)\nEstimated primary completion: 13 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/setmelanotide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06760546
URL:https://assetmemo.bio/drug/setmelanotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467447-118@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:retatrutide: Phase 2 readout est. (NCT07467447)
DESCRIPTION:retatrutide\, phase 2\, Obesity.\nStudy: Effect of Retatrutide 
 Versus Placebo in Participants Who Have Obesity or Are Overweight\nEstimat
 ed primary completion: 14 March 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/retatrutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07467447
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282743-274@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Utreglutide: Phase 2 readout est. (NCT07282743)
DESCRIPTION:Utreglutide\, phase 2\, Obesity.\nStudy: Efficacy and Safety of
  GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/utreglutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07282743
URL:https://assetmemo.bio/drug/utreglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06811324-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06811324)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Effects of 
 Tirzepatide on Muscle and Vascular Health in Obese Older Adults\nEstimated
  primary completion: 1 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06811324
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987695-143@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT069876
 95)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in J
 apan Who Have Obesity Disease\nEstimated primary completion: 27 April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglu
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06987695
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463846-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Tirzepatide (Zepbound): Phase 1/2 readout est. (NCT07463846)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 1/2\, Obesity.\nStudy: A Study t
 o Evaluate ALN-2232 in Participants With Obesity\nEstimated primary comple
 tion: 28 April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tirzepatide-zepbound#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07463846
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07496463-123@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Imcivree (setmelanotide): Phase 2 readout est. (NCT07496463)
DESCRIPTION:Imcivree (setmelanotide)\, phase 2\, Obesity.\nStudy: Setmelano
 tide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (
 PHP1a)\nEstimated primary completion: 30 April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/setmelanotide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07496463
URL:https://assetmemo.bio/drug/setmelanotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07458269-185@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:ribupatide: Phase 2 readout est. (NCT07458269)
DESCRIPTION:ribupatide\, phase 2\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With
  Obesity Who Do Not Have Diabetes\nEstimated primary completion: May 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07458269
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570758-275@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:ERX1000: Phase 2 readout est. (NCT07570758)
DESCRIPTION:ERX1000\, phase 2\, Obesity.\nStudy: A Phase 2A Clinical Trial 
 to Assess the Safety and Tolerability of ERX1000 in Men and Women for the 
 Treatment of Obesity.\nEstimated primary completion: May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/erx1000#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07570758
URL:https://assetmemo.bio/drug/erx1000#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239116-255@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270507
DTEND;VALUE=DATE:20270508
SUMMARY:RM-718: Phase 1/2 readout est. (NCT06239116)
DESCRIPTION:RM-718\, phase 1/2\, Obesity.\nStudy: A Study of RM-718 in Heal
 thy Subjects and Patients With MC4R Pathway Impairment\nEstimated primary 
 completion: 7 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/rm-718#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06239116
URL:https://assetmemo.bio/drug/rm-718#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931028-183@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270507
DTEND;VALUE=DATE:20270508
SUMMARY:mazdutide: Phase 3 readout est. (NCT06931028)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study of IBI362 in Chi
 nese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2\nEstimated p
 rimary completion: 7 May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/mazdutide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06931028
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220642-120@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270511
DTEND;VALUE=DATE:20270512
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07220642)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: Weight Loss in People
  Living With Overweight or Obesity Following Treatment With Cagrilintide\n
 Estimated primary completion: 11 May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cagrilintide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07220642
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220759-120@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07220759)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: Weight Loss in People
  Living With Overweight or Obesity and Type 2 Diabetes Following Treatment
  With Cagrilintide\nEstimated primary completion: 12 May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07220759
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07292519-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07292519)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
  Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol
  Use Disorder (AUD) and Overweight/Obesity (OOB)\nEstimated primary comple
 tion: 15 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ti
 rzepatide-zepbound#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07292519
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745504-120@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07745504)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: A Research Study to C
 ompare Two Different Versions of Injectable Cagrilintide and Placebo in Pe
 ople With Excess Body Weight\nEstimated primary completion: 18 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07745504
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230119-202@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270529
DTEND;VALUE=DATE:20270530
SUMMARY:zovaglutide: Phase 3 readout est. (NCT07230119)
DESCRIPTION:zovaglutide\, phase 3\, Obesity.\nStudy: A Study of Zovaglutide
  in Subjects With Overweight or Obesity (HORIZON-1)\nEstimated primary com
 pletion: 29 May 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /zovaglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07230119
URL:https://assetmemo.bio/drug/zovaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07411378-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07411378)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Testing the E
 fficacy\, Safety\, and PK of 20E in Patients With Obesity Who Are Starting
  Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.\nEstimated 
 primary completion: June 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07411378
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232719-118@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:retatrutide: Phase 3 readout est. (NCT07232719)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants With Obesity or Overweight\nEstimated primary
  completion: June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/retatrutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07232719
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07274137-248@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:MDR-001: Phase 3 readout est. (NCT07274137)
DESCRIPTION:MDR-001\, phase 3\, Obesity.\nStudy: A Phase III Study to Evalu
 ate the Efficacy and Safety of MDR-001 in Adult Participants With Overweig
 ht or Obesity (MOBILE）\nEstimated primary completion: June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/mdr-001#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07274137
URL:https://assetmemo.bio/drug/mdr-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738276-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07738276)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Evaluation 
 of the Efficacy and Safety of Tirzepatide\, a Dual GLP-1/GIP Agonist\, on 
 Functional Capacity in Reduced Ejection Fraction Heart Failure Patients Wi
 th Obesity\nEstimated primary completion: 11 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07738276
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639021-138@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:NNC0662-0419: Phase 2 readout est. (NCT07639021)
DESCRIPTION:NNC0662-0419\, phase 2\, Obesity.\nStudy: A Research Study Comp
 aring Different Ways of Increasing the Dose of NNC0662-0419 in Participant
 s With Obesity\nEstimated primary completion: 14 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nnc0662-0419#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07639021
URL:https://assetmemo.bio/drug/nnc0662-0419#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639021-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07639021)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: A Research St
 udy Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Par
 ticipants With Obesity\nEstimated primary completion: 14 June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07639021
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871409-143@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT078714
 09)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Home Self-administration of Maridebart Cafraglutide With Autoinjector in 
 Adults Living With Obesity or Overweight\nEstimated primary completion: 16
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maridebar
 t-cafraglutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07871409
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220772-147@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:mibavademab: Phase 3 readout est. (NCT07220772)
DESCRIPTION:mibavademab\, phase 3\, Obesity.\nStudy: A Study Evaluating Mib
 avademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Childr
 en\, Adolescents and Adults\nEstimated primary completion: 18 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/mibavademab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07220772
URL:https://assetmemo.bio/drug/mibavademab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662122-153@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270626
DTEND;VALUE=DATE:20270627
SUMMARY:BI 3034701: Phase 2 readout est. (NCT07662122)
DESCRIPTION:BI 3034701\, phase 2\, Obesity.\nStudy: A Study to Test Whether
  BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweigh
 t\nEstimated primary completion: 26 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bi-3034701#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07662122
URL:https://assetmemo.bio/drug/bi-3034701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150975-190@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07150975)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Phase III Clinical St
 udy Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (
 Wegovy®) in Adult Obese or Overweight Subjects\nEstimated primary complet
 ion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bo
 fanglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07150975
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671391-242@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:LAE102: Phase 2 readout est. (NCT07671391)
DESCRIPTION:LAE102\, phase 2\, Obesity.\nStudy: A Randomized\, Double-blind
 \, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in C
 ombination With Tirzepatide on Body in Obese Participants\nEstimated prima
 ry completion: July 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lae102#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07671391
URL:https://assetmemo.bio/drug/lae102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671391-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07671391)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: A Randomize
 d\, Double-blind\, Placebo-controlled Study Evaluating the Effect of LAE10
 2 Injection in Combination With Tirzepatide on Body in Obese Participants\
 nEstimated primary completion: July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07671391
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104383-178@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:VK2735: Phase 3 readout est. (NCT07104383)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: VK2735 for Weight Managemen
 t Type 2 Diabetes Phase 3 (VANQUISH 2)\nEstimated primary completion: 1 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/vk2735#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07104383
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104500-178@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:VK2735: Phase 3 readout est. (NCT07104500)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: VK2735 for Weight Managemen
 t Phase 3\nEstimated primary completion: 1 July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/vk2735#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07104500
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497880-186@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270707
DTEND;VALUE=DATE:20270708
SUMMARY:Safiglipron (HRS-7535): Phase 2 readout est. (NCT07497880)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 2\, Obesity.\nStudy: Efficacy an
 d Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Ove
 rweight With at Least 1 Weight-Related Comorbidity\nEstimated primary comp
 letion: 7 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 safiglipron-hrs-7535#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07497880
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629544-225@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:DA-302168S: Phase 3 readout est. (NCT07629544)
DESCRIPTION:DA-302168S\, phase 3\, Obesity.\nStudy: A Study of DA-302168S i
 n Participants With Overweight/Obesity\nEstimated primary completion: 9 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/da-302168s#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07629
 544
URL:https://assetmemo.bio/drug/da-302168s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972459-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06972459)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and a
 t Least One Weight-Related Comorbidity\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 72459
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972472-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06972472)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and T
 ype 2 Diabetes\nEstimated primary completion: August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/orforglipron#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06972472
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993792-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06993792)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol for Orforglipron (LY3502970) in Participants With Obesity or Overw
 eight With and Without Type 2 Diabetes\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 93792
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918625-201@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:BGM1812: Phase 2 readout est. (NCT07918625)
DESCRIPTION:BGM1812\, phase 2\, Obesity.\nStudy: A Study to Evaluate Effica
 cy and Safety of BGM1812 Injection in Overweight or Obese Participants Wit
 hout Diabetes\nEstimated primary completion: 1 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bgm1812#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07918625
URL:https://assetmemo.bio/drug/bgm1812#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575932-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270804
DTEND;VALUE=DATE:20270805
SUMMARY:Berobenatide: Phase 2 readout est. (NCT07575932)
DESCRIPTION:Berobenatide\, phase 2\, Obesity.\nStudy: A Study of PF-0865394
 5 and PF-08653944 in Adults With Overweight or Obesity\nEstimated primary 
 completion: 4 August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/berobenatide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07575932
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575932-180@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270804
DTEND;VALUE=DATE:20270805
SUMMARY:MET-233i: Phase 2 readout est. (NCT07575932)
DESCRIPTION:MET-233i\, phase 2\, Obesity.\nStudy: A Study of PF-08653945 an
 d PF-08653944 in Adults With Overweight or Obesity\nEstimated primary comp
 letion: 4 August 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/met-233i#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07575932
URL:https://assetmemo.bio/drug/met-233i#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06732245-250@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:NA-931: Phase 2 readout est. (NCT06732245)
DESCRIPTION:NA-931\, phase 2\, Obesity.\nStudy: Safety and Efficacy of NA-9
 31 and Tirzepatide in Adults Who Are Overweight or Obese\nEstimated primar
 y completion: 15 August 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/na-931#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06732245
URL:https://assetmemo.bio/drug/na-931#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06732245-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06732245)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Safety and 
 Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese\n
 Estimated primary completion: 15 August 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06732245
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225686-143@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT072256
 86)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstruc
 tive Sleep Apnea on Positive Airway Pressure Therapy\nEstimated primary co
 mpletion: 20 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07225686
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441252-143@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:MariTide (maridebart cafraglutide): Phase 2 readout est. (NCT074412
 52)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 2\, Obesity.\nStudy:
  A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adu
 lts Living With Elevated Liver Fat and Obesity or Overweight\nEstimated pr
 imary completion: 25 August 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07441252
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143956-183@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:mazdutide: Phase 2 readout est. (NCT06143956)
DESCRIPTION:mazdutide\, phase 2\, Obesity.\nStudy: A Master Protocol Study 
 (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Pa
 rticipants With Obesity or Overweight\nEstimated primary completion: Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mazdutide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614
 3956
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143956-245@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:macupatide: Phase 2 readout est. (NCT06143956)
DESCRIPTION:macupatide\, phase 2\, Obesity.\nStudy: A Master Protocol Study
  (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult P
 articipants With Obesity or Overweight\nEstimated primary completion: Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/macupatid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 143956
URL:https://assetmemo.bio/drug/macupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589608-245@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:macupatide: Phase 2 readout est. (NCT07589608)
DESCRIPTION:macupatide\, phase 2\, Obesity.\nStudy: A Study to Investigate 
 Weight Management With Macupatide and Eloralintide\, Alone or in Combinati
 on\, in Adult Participants With Obesity or Overweight\nEstimated primary c
 ompletion: September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/macupatide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07589608
URL:https://assetmemo.bio/drug/macupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143956-278@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:eloralintide: Phase 2 readout est. (NCT06143956)
DESCRIPTION:eloralintide\, phase 2\, Obesity.\nStudy: A Master Protocol Stu
 dy (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult
  Participants With Obesity or Overweight\nEstimated primary completion: Se
 ptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elorali
 ntide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06143956
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589608-278@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:eloralintide: Phase 2 readout est. (NCT07589608)
DESCRIPTION:eloralintide\, phase 2\, Obesity.\nStudy: A Study to Investigat
 e Weight Management With Macupatide and Eloralintide\, Alone or in Combina
 tion\, in Adult Participants With Obesity or Overweight\nEstimated primary
  completion: September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/eloralintide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07589608
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143956-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06143956)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: A Master Pr
 otocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs
 ) in Adult Participants With Obesity or Overweight\nEstimated primary comp
 letion: September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tirzepatide-zepbound#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06143956
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948422-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06948422)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol for Orforglipron (LY3502970) in Participants With Hypertension and
  Obesity or Overweight: (ATTAIN-Hypertension Screening)\nEstimated primary
  completion: September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06948422
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948435-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06948435)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol Study of Orforglipron (LY3502970) in Participants With Hypertensio
 n and Obesity or Overweight (ATTAIN-Hypertension) GZL1\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06948435
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952530-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06952530)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol Study of Orforglipron (LY3502970) in Participants With Hypertensio
 n and Obesity or Overweight (ATTAIN-Hypertension) GZL2\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06952530
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07035093-118@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:retatrutide: Phase 3 readout est. (NCT07035093)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Lo
 w Back Pain\nEstimated primary completion: September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07035093
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07929298-193@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270903
DTEND;VALUE=DATE:20270904
SUMMARY:ecnoglutide: Phase 2 readout est. (NCT07929298)
DESCRIPTION:ecnoglutide\, phase 2\, Obesity.\nStudy: A Study to Evaluate th
 e Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With 
 Overweight or Obesity\nEstimated primary completion: 3 September 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ecnoglutide#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07929298
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311850-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270921
DTEND;VALUE=DATE:20270922
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07311850)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety o
 f MET097 Once-Weekly in People With Overweight or Obesity\nEstimated prima
 ry completion: 21 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07311850
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648225-199@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:UBT251: Phase 3 readout est. (NCT07648225)
DESCRIPTION:UBT251\, phase 3\, Obesity.\nStudy: UBT251 Injection Phase Ⅲ 
 Study (Overweight or Obesity)\nEstimated primary completion: 29 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07648225
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06518837-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06518837)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
  for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER
 2 Negative Breast Cancer\nEstimated primary completion: 30 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 18837
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446998-264@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:enobosarm: Phase 2 readout est. (NCT07446998)
DESCRIPTION:enobosarm\, phase 2\, Obesity.\nStudy: Proof-of-Concept Study E
 valuating Total Body Weight\, Physical Function & Safety of Enobosarm in P
 atients Treated With GLP-1 Receptor Agonist\, for Weight Loss\nEstimated p
 rimary completion: October 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/enobosarm#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07446998
URL:https://assetmemo.bio/drug/enobosarm#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05556512-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT05556512)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adu
 lts With Obesity\nEstimated primary completion: October 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05556512
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439277-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06439277)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (
 SURMOUNT-ADOLESCENTS-2)\nEstimated primary completion: October 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06439277
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400653-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07400653)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine (PF-08653944) in People With Obesity or Overweight an
 d Type 2 Diabetes (T2D)\nEstimated primary completion: 12 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07400653
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06700538-174@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:ARO-INHBE: Phase 1/2 readout est. (NCT06700538)
DESCRIPTION:ARO-INHBE\, phase 1/2\, Obesity.\nStudy: A First-In-Human Study
  of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mell
 itus\nEstimated primary completion: 15 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/aro-inhbe#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06700538
URL:https://assetmemo.bio/drug/aro-inhbe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255209-183@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:mazdutide: Phase 3 readout est. (NCT07255209)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study of IBI362 in Chi
 nese Adolescents With Obesity or Overweight\nEstimated primary completion:
  31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maz
 dutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07255209
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670884-185@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ribupatide: Phase 3 readout est. (NCT07670884)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Eva
 luate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Su
 bjects\nEstimated primary completion: 31 October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ribupatide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07670884
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228741-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07228741)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Resistance 
 Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of A
 LL With Obesity\nEstimated primary completion: November 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07228741
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589686-159@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:enicepatide: Phase 2 readout est. (NCT07589686)
DESCRIPTION:enicepatide\, phase 2\, Obesity.\nStudy: A Dose-Finding Study o
 f Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Over
 weight\nEstimated primary completion: 12 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/enicepatide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07589686
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589686-162@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:petrelintide: Phase 2 readout est. (NCT07589686)
DESCRIPTION:petrelintide\, phase 2\, Obesity.\nStudy: A Dose-Finding Study 
 of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Ove
 rweight\nEstimated primary completion: 12 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/petrelintide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07589686
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493057-190@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07493057)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Evaluate the Efficacy
  and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Ap
 nea Not Treated With Positive Airway Pressure (PAP) Therapy\nEstimated pri
 mary completion: 14 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bofanglutide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07493057
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06842186-270@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:WVE-007: Phase 1/2 readout est. (NCT06842186)
DESCRIPTION:WVE-007\, phase 1/2\, Obesity.\nStudy: A Phase 1/2a Study of WV
 E-007 in Adults Living With Overweight or Obesity\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /wve-007#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06842186
URL:https://assetmemo.bio/drug/wve-007#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622810-190@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07622810)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: BALANCE-OBS: Bofanglu
 tide (GZR18) Versus Semaglutide in Latin American Adults With Overweight o
 r Obesity\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bofanglutide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07622810
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672939-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06672939)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Adolescent Participants With Obesity\, or Ove
 rweight With Related Comorbidities\nEstimated primary completion: December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06672
 939
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528027-186@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Safiglipron (HRS-7535): Phase 3 readout est. (NCT07528027)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 3\, Obesity.\nStudy: Phase III S
 tudy of HRS-7535 for Hypertension With Overweight or Obesity\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07528027
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06499857-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT06499857)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Semaglutide f
 or Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation\nE
 stimated primary completion: December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06499857
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06847399-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06847399)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Efficacy an
 d Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for 
 Binge-Eating Disorder\nEstimated primary completion: 1 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06847399
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387094-193@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271216
DTEND;VALUE=DATE:20271217
SUMMARY:ecnoglutide: Phase 3 readout est. (NCT07387094)
DESCRIPTION:ecnoglutide\, phase 3\, Obesity.\nStudy: A Study of XW003 in Ob
 ese Participants With Obstructive Sleep Apnea But Not Receive Positive Air
 way Pressure Therapy\nEstimated primary completion: 16 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ecnoglutide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07387094
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684144-143@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271226
DTEND;VALUE=DATE:20271227
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT076841
 44)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Extension Trial to Evaluate the Long-term Efficacy\, Safety\, and Tolerab
 ility of Maridebart Cafraglutide (MARITIME-2-EXTENSION)\nEstimated primary
  completion: 26 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07684144
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684235-143@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271226
DTEND;VALUE=DATE:20271227
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT076842
 35)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Extension Trial to Evaluate the Long-term Efficacy\, Safety\, and Tolerab
 ility of Maridebart Cafraglutide (MARITIME-1-EXTENSION)\nEstimated primary
  completion: 26 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07684235
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05746039-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Semaglutide (Wegovy): Phase 1/2 readout est. (NCT05746039)
DESCRIPTION:Semaglutide (Wegovy)\, phase 1/2\, Obesity.\nStudy: Feasibility
  of Semaglutide in Advanced Lung Disease\nEstimated primary completion: 28
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semag
 lutide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05746039
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423599-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Semaglutide (Wegovy): Phase 2/3 readout est. (NCT06423599)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2/3\, Obesity.\nStudy: Effect of W
 eight Loss on Physical and Cardiac Performance in People With Obesity and 
 Heart Failure\nEstimated primary completion: 30 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06423599
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282600-278@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:eloralintide: Phase 3 readout est. (NCT07282600)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity or Overweight\, and Type 2 Dia
 betes\nEstimated primary completion: January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07282600
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575399-143@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280103
DTEND;VALUE=DATE:20280104
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT075753
 99)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy\, Safety and Tolerability of Switching From Glucagon-like Peptid
 e-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With 
 Obesity or Overweight (MARITIME-SWITCH)\nEstimated primary completion: 3 J
 anuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/marideba
 rt-cafraglutide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07575399
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812597-202@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280113
DTEND;VALUE=DATE:20280114
SUMMARY:zovaglutide: Phase 2 readout est. (NCT07812597)
DESCRIPTION:zovaglutide\, phase 2\, Obesity.\nStudy: A Study Evaluating Saf
 ety and Tolerability of Switching From Semaglutide to Zovaglutide in Adult
 s With Obesity (HORIZON-SWITCH-SZ)\nEstimated primary completion: 13 Janua
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/zovaglutide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0781
 2597
URL:https://assetmemo.bio/drug/zovaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685808-144@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280121
DTEND;VALUE=DATE:20280122
SUMMARY:olatorepatide: Phase 2 readout est. (NCT07685808)
DESCRIPTION:olatorepatide\, phase 2\, Obesity.\nStudy: Study of Olatorepati
 de in Adult Participants Living With Overweight or Obesity Without Diabete
 s\nEstimated primary completion: 21 January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/olatorepatide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07685808
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07857473-261@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:TE-8105: Phase 2 readout est. (NCT07857473)
DESCRIPTION:TE-8105\, phase 2\, Obesity.\nStudy: A Study to Investigate the
  Safety and Efficacy of TE-8105 in Overweight or Obesity Participants\nEst
 imated primary completion: February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/te-8105#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07857473
URL:https://assetmemo.bio/drug/te-8105#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284875-185@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284875)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide in Participants Living With Obesity or Overweight With Weight-R
 elated Comorbidities Who Do Not Have Diabetes\nEstimated primary completio
 n: February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rib
 upatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07284875
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845500-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07845500)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) 
 to Help Keep Weight Off in People With Overweight or Obesity\nEstimated pr
 imary completion: 16 February 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07845500
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770841-11055@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280222
DTEND;VALUE=DATE:20280223
SUMMARY:Semaglutide (Wegovy tablets): Phase 3 readout est. (NCT07770841)
DESCRIPTION:Semaglutide (Wegovy tablets)\, phase 3\, Obesity.\nStudy: Resea
 rch Study on How Well Oral Semaglutide Works for Weight Loss in Adults Wit
 h Excess Body Weight\nEstimated primary completion: 22 February 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy-tablet
 s#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 770841
URL:https://assetmemo.bio/drug/semaglutide-wegovy-tablets#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564414-121@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280223
DTEND;VALUE=DATE:20280224
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0756
 4414)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Look at How Two Different Doses of CagriSema and On
 e Dose of Semaglutide Help People Living With Obesity With or Without Type
  2 Diabetes Lose Weight\nEstimated primary completion: 23 February 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide-semagluti
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7564414
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670416-159@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:enicepatide: Phase 3 readout est. (NCT07670416)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Study to Evaluate th
 e Effects of Enicepatide in Participants With Obesity or Overweight\, With
  or Without Type 2 Diabetes\nEstimated primary completion: 24 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07670416
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752979-172@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:ABBV-295: Phase 2 readout est. (NCT07752979)
DESCRIPTION:ABBV-295\, phase 2\, Obesity.\nStudy: Safety and Efficacy of AB
 BV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidit
 ies\nEstimated primary completion: March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/abbv-295#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07752979
URL:https://assetmemo.bio/drug/abbv-295#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284979-185@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284979)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo 
 in Participants Living With Obesity Who Do Not Have Diabetes\nEstimated pr
 imary completion: March 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ribupatide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07284979
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790861-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07790861)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweig
 ht and Weight-Related Health Problems\nEstimated primary completion: March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07790
 861
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07787260-196@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:HDM1005: Phase 3 readout est. (NCT07787260)
DESCRIPTION:HDM1005\, phase 3\, Obesity.\nStudy: A Phase III\, Multicenter\
 , Randomized\, Double-Blind\, Placebo-Controlled Clinical Study to Evaluat
 e the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructiv
 e Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PA
 P) Therapy\nEstimated primary completion: March 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07787260
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07202884-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07202884)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron in Female Participants With Stress Urinary Incontinence Who 
 Have Obesity or Overweight\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07202884
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321886-278@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07321886)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity\, or Overweight Without Type 2
  Diabetes\nEstimated primary completion: March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07321886
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353931-278@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07353931)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: Efficacy and Safety o
 f Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain a
 nd Obesity or Overweight\nEstimated primary completion: March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/eloralintide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07353931
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07369011-278@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07369011)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or
  Overweight\nEstimated primary completion: March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07369011
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07792954-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280314
DTEND;VALUE=DATE:20280315
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07792954)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Plac
 ebo in Chinese Adults With Overweight or Obesity\nEstimated primary comple
 tion: 14 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 berobenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07792954
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284901-185@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284901)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide Administered Once Weekly in Participants Living With Obesity or
  Overweight and Diabetes\nEstimated primary completion: 27 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07284901
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153471-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07153471)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and O
 steoarthritis (OA) of the Knee\nEstimated primary completion: April 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07153471
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859268-118@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:retatrutide: Phase 3 readout est. (NCT06859268)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in the Maintenance of Weight Reduction in Individuals With Ob
 esity\nEstimated primary completion: April 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06859268
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937086-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06937086)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Mirikizumab
  Administered at the Same Time as Tirzepatide in Adult Participants With M
 oderately to Severely Active Ulcerative Colitis and Obesity or Overweight:
  Phase 3b Study\nEstimated primary completion: April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06937086
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775404-148@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280406
DTEND;VALUE=DATE:20280407
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07775404)
DESCRIPTION:elecoglipron\, phase 3\, Obesity.\nStudy: A Study to Investigat
 e the Efficacy and Safety of Elecoglipron in Asian Participants With Obesi
 ty or Overweight With or Without Type 2 Diabetes Mellitus\nEstimated prima
 ry completion: 6 April 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/elecoglipron#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07775404
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823608-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07823608)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Monthly Dosing Study Medicine Called Berobenatide in Adults With Bre
 athing Problems During Sleep and Overweight or Obesity Who Use a Breathing
  Machine (PAP) (VESPER-OSA 1)\nEstimated primary completion: 30 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07823608
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937099-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06937099)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Crohn's Disease.\nStudy: Mir
 ikizumab and Tirzepatide Administered in Adult Participants With Moderatel
 y to Severely Active Crohn's Disease and Obesity or Overweight\nEstimated 
 primary completion: May 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06937099
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595549-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280504
DTEND;VALUE=DATE:20280505
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07595549)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called Berobenatide (PF-08653944) in People With Over
 weight or Obesity\nEstimated primary completion: 4 May 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/berobenatide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07595549
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06173778-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280525
DTEND;VALUE=DATE:20280526
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT06173778)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Semaglutide f
 or Post-Smoking Cessation Weight Management\nEstimated primary completion:
  25 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglu
 tide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06173778
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734311-193@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:ecnoglutide: Phase 3 readout est. (NCT07734311)
DESCRIPTION:ecnoglutide\, phase 3\, Obesity.\nStudy: A Study of Econoglutid
 e Injection in Obese Participants With Knee Osteoarthritis (KOA)\nEstimate
 d primary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ecnoglutide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07734311
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05912621-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT05912621)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
 : Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With O
 verweight/Obesity\nEstimated primary completion: June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05912621
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909006-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT06909006)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Semaglutide T
 reatment in Type 1 Diabetes\nEstimated primary completion: June 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06909006
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392190-278@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:eloralintide: Phase 3 readout est. (NCT07392190)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Persistent Obesity Who Are Treated Wit
 h a Weekly Incretin\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/eloralintide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07392190
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919405-121@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0791
 9405)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Investigate How Well the Medicine CagriSema Lowers 
 High Blood Pressure in People Living With High Blood Pressure and Obesity\
 nEstimated primary completion: 1 June 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07919405
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881757-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07881757)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Monthly Dosing Study Medicine Called Berobenatide in Adults With Bre
 athing Problems During Sleep and Overweight or Obesity Who Do Not Use a Br
 eathing Machine (PAP) (VESPER-OSA 2)\nEstimated primary completion: 1 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07881
 757
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503210-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07503210)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 12: A Research S
 tudy Investigating How Well the Medicine NNC0487-0111 Helps People With Ex
 cess Body Weight Maintain Their Weight Loss\nEstimated primary completion:
  6 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagam
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07503210
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874633-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07874633)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Pla
 cebo in Chinese Adults With Overweight or Obesity\nEstimated primary compl
 etion: 6 June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 erobenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07874633
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836270-193@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280608
DTEND;VALUE=DATE:20280609
SUMMARY:ecnoglutide: Phase 3 readout est. (NCT07836270)
DESCRIPTION:ecnoglutide\, phase 3\, Obesity.\nStudy: A Study of Ecnoglutide
  Injection in Overweight or Obese Chinese Adolescents\nEstimated primary c
 ompletion: 8 June 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ecnoglutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07836270
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07434050-193@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280619
DTEND;VALUE=DATE:20280620
SUMMARY:ecnoglutide: Phase 3 readout est. (NCT07434050)
DESCRIPTION:ecnoglutide\, phase 3\, Obesity.\nStudy: A Study of XW003 in Ob
 ese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pr
 essure Therapy\nEstimated primary completion: 19 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ecnoglutide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07434050
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571109-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07571109)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 4: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway 
 Pressure Lose Weight and Improve Sleep Apnoea\nEstimated primary completio
 n: 26 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zena
 gamtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07571109
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720271-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280627
DTEND;VALUE=DATE:20280628
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07720271)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 9: A Research St
 udy Investigating How Well Zenagamtide Tablets Help People With Excess Bod
 y Weight Lose Weight\nEstimated primary completion: 27 June 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07720271
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037433-143@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT070374
 33)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcom
 es in Participants With Atherosclerotic Cardiovascular Disease and Overwei
 ght or Obesity\nEstimated primary completion: 30 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07037433
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037459-143@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT070374
 59)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced
  Ejection Fraction and Obesity\nEstimated primary completion: 30 June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglu
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07037459
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07868835-178@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:VK2735: Phase 3 readout est. (NCT07868835)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: Oral VK2735 for Weight Mana
 gement Phase 3 (SUNRISE 1)\nEstimated primary completion: July 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/vk2735#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07868835
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743450-211@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:ASC30: Phase 3 readout est. (NCT07743450)
DESCRIPTION:ASC30\, phase 3\, Obesity.\nStudy: A Study of Once-daily Oral A
 SC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesit
 y or Overweight With Type 2 Diabetes\nEstimated primary completion: July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/asc30#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07743450
URL:https://assetmemo.bio/drug/asc30#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743463-211@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:ASC30: Phase 3 readout est. (NCT07743463)
DESCRIPTION:ASC30\, phase 3\, Obesity.\nStudy: A Study of Once-daily Oral A
 SC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesit
 y or Overweight With Weight-Related Comorbidities\nEstimated primary compl
 etion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/asc
 30#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7743463
URL:https://assetmemo.bio/drug/asc30#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571005-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280712
DTEND;VALUE=DATE:20280713
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07571005)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 3: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Air
 way Pressure Lose Weight and Improve Sleep Apnoea\nEstimated primary compl
 etion: 12 July 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zenagamtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07571005
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351045-159@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280724
DTEND;VALUE=DATE:20280725
SUMMARY:enicepatide: Phase 3 readout est. (NCT07351045)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Ev
 aluate the Effects of Enicepatide (RO7795068) in Participants With Obesity
  or Overweight Without Type 2 Diabetes\nEstimated primary completion: 24 J
 uly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 51045
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850050-119@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280726
DTEND;VALUE=DATE:20280727
SUMMARY:survodutide: Phase 3 readout est. (NCT07850050)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: SYNCHRONIZE®-HERA: A 
 Study to Test Whether Survodutide Helps Women Who Are Living With Overweig
 ht or Obesity and Are Going Through or Have Finished Menopause\, to Lose W
 eight\nEstimated primary completion: 26 July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/survodutide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07850050
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667803-148@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07667803)
DESCRIPTION:elecoglipron\, phase 3\, Obesity.\nStudy: A Master Protocol to 
 Investigate Efficacy and Safety of Elecoglipron in Participants With Obesi
 ty or Overweight With or Without T2DM\nEstimated primary completion: 31 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 67803
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07533175-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07533175)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 2: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Type 2 Diabetes Lose Weight\nEstimated primary complet
 ion: 7 August 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/z
 enagamtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07533175
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351058-159@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:enicepatide: Phase 3 readout est. (NCT07351058)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Ev
 aluate the Effects of Enicepatide (RO7795068) in Participants With Obesity
  or Overweight and Type 2 Diabetes\nEstimated primary completion: 7 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073510
 58
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776509-149@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280809
DTEND;VALUE=DATE:20280810
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07776509)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate E
 ffect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Partic
 ipants With Obesity or Overweight With Weight-related Comorbidity With or 
 Without Type 2 Diabetes Mellitus\nEstimated primary completion: 9 August 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/lenbelintide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0777650
 9
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784270-149@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280809
DTEND;VALUE=DATE:20280810
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07784270)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate E
 ffect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and O
 besity or Overweight\nEstimated primary completion: 9 August 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/lenbelintide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07784270
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784725-149@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280811
DTEND;VALUE=DATE:20280812
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07784725)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate E
 ffect of AZD6234 in Adult Participants With Obesity or Overweight With Wei
 ght-related Comorbidity Without Type 2 Diabetes Mellitus\nEstimated primar
 y completion: 11 August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenbelintide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07784725
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07481630-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280814
DTEND;VALUE=DATE:20280815
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07481630)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study Inves
 tigating How Well the Medicine NNC0487-0111 Helps People With Excess Body 
 Weight and Knee Osteoarthritis Lose Weight and Reduce Pain\nEstimated prim
 ary completion: 14 August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zenagamtide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07481630
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509307-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280814
DTEND;VALUE=DATE:20280815
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07509307)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 6: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain\nEstim
 ated primary completion: 14 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07509307
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747805-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07747805)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: GLP-1 Agoni
 sts for Lung Function Improvement and Muscle Restoration in COPD\nEstimate
 d primary completion: 15 August 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07747805
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915609-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280821
DTEND;VALUE=DATE:20280822
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07915609)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Ov
 erweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)\nEstimat
 ed primary completion: 21 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07915609
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919678-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280822
DTEND;VALUE=DATE:20280823
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07919678)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Study Medicine Called Berobenatide in Adults With Knee Pain and Overweig
 ht or Obesity (VESPER-OA 1)\nEstimated primary completion: 22 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07919678
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794397-196@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:HDM1005: Phase 3 readout est. (NCT07794397)
DESCRIPTION:HDM1005\, phase 3\, Obesity.\nStudy: A Phase III\, Multicenter\
 , Randomized\, Double-Blind\, Placebo-Controlled Clinical Study to Evaluat
 e the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructiv
 e Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) T
 herapy\nEstimated primary completion: September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07794397
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767942-199@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:UBT251: Phase 3 readout est. (NCT07767942)
DESCRIPTION:UBT251\, phase 3\, Obesity.\nStudy: UBT251 Injection Phase Ⅲ 
 Study (OSA-NPAP)\nEstimated primary completion: September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07767942
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654361-177@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:aleniglipron: Phase 3 readout est. (NCT07654361)
DESCRIPTION:aleniglipron\, phase 3\, Obesity.\nStudy: Efficacy and Safety o
 f Aleniglipron in Participants With Obesity or Overweight With a Weight-Re
 lated Comorbidity (ACCOMPLISH-1)\nEstimated primary completion: September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/aleniglipron#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076543
 61
URL:https://assetmemo.bio/drug/aleniglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654374-177@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:aleniglipron: Phase 3 readout est. (NCT07654374)
DESCRIPTION:aleniglipron\, phase 3\, Obesity.\nStudy: A Study of Aleniglipr
 on in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCO
 MPLISH-2)\nEstimated primary completion: September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/aleniglipron#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07654374
URL:https://assetmemo.bio/drug/aleniglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294950-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT07294950)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Impact of Sem
 aglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Ba
 lance: Recovery Effects After Semaglutide Termination\nEstimated primary c
 ompletion: September 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07294950
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07922330-149@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07922330)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate t
 he Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adu
 lts Who Are Obese or Overweight. These Participants May or May Not Also Ha
 ve Type 2 Diabetes\nEstimated primary completion: 15 September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lenbelintide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07922330
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501832-190@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280928
DTEND;VALUE=DATE:20280929
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07501832)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Evaluate the Efficacy
  and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Ap
 nea Receiving Positive Airway Pressure (PAP) Therapy\nEstimated primary co
 mpletion: 28 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bofanglutide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07501832
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743983-200@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:BGM0504: Phase 3 readout est. (NCT07743983)
DESCRIPTION:BGM0504\, phase 3\, Obesity.\nStudy: A Study of BGM0504 in Earl
 y T2DM With Obesity\nEstimated primary completion: 30 September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/bgm0504#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07743983
URL:https://assetmemo.bio/drug/bgm0504#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357415-118@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:retatrutide: Phase 3 readout est. (NCT07357415)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or O
 verweight\nEstimated primary completion: October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07357415
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07868939-178@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:VK2735: Phase 3 readout est. (NCT07868939)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: Oral VK2735 for Weight Mana
 gement in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)\nEstima
 ted primary completion: October 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/vk2735#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07868939
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668414-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281010
DTEND;VALUE=DATE:20281011
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07668414)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study Inves
 tigating How Well the Medicine Zenagamtide Helps People With Excess Body W
 eight Lose Weight Compared to Semaglutide\nEstimated primary completion: 1
 0 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenag
 amtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07668414
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932925-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07932925)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Safety and Effectiveness of Berobenatide in Women With Urine Leakage
  and With Obesity or Overweight (VESPER-SUI)\nEstimated primary completion
 : 13 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/be
 robenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07932925
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843485-162@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843485)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity and Type 2 Diabetes\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/petrelint
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07843485
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709910-185@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:ribupatide: Phase 3 readout est. (NCT07709910)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Trial of Ribupatide I
 njection in Participants With Obesity and Knee Osteoarthritis\nEstimated p
 rimary completion: November 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/ribupatide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07709910
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830329-144@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:olatorepatide: Phase 2 readout est. (NCT07830329)
DESCRIPTION:olatorepatide\, phase 2\, Obesity.\nStudy: Efficacy and Safety 
 of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidraden
 itis Suppurativa Living With Overweight or Obesity\nEstimated primary comp
 letion: 24 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/olatorepatide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07830329
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07702890-170@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:GUB-UCN2: Phase 1/2 readout est. (NCT07702890)
DESCRIPTION:GUB-UCN2\, phase 1/2\, Obesity.\nStudy: A Three-part First-in-h
 uman Trial to Assess Safety\, Tolerability\, Pharmacokinetics and Pharmaco
 dynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participan
 ts With T2D\nEstimated primary completion: December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/gub-ucn2#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07702890
URL:https://assetmemo.bio/drug/gub-ucn2#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06180616-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06180616)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
  for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
 \nEstimated primary completion: December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06180616
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829198-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07829198)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Efficacy of
  Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss
  After Bariatric Surgery: A Randomized\, Double-Blind\, Placebo-Controlled
  Clinical Trial\nEstimated primary completion: December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07829198
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846865-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Tirzepatide (Zepbound): Phase 2/3 readout est. (NCT07846865)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2/3\, Obesity.\nStudy: Tirzepati
 de Versus Positive Airway Pressure for the Treatment of Obstructive Sleep 
 Apnoea\nEstimated primary completion: 1 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07846865
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400107-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281219
DTEND;VALUE=DATE:20281220
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07400107)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 8: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Compared to Semagluti
 de Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight\nE
 stimated primary completion: 19 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07400107
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896265-144@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281219
DTEND;VALUE=DATE:20281220
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07896265)
DESCRIPTION:olatorepatide\, phase 3\, Obesity.\nStudy: Efficacy And Safety 
 of Olatorepatide in Adults With Overweight or Obesity Without Diabetes\nEs
 timated primary completion: 19 December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/olatorepatide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07896265
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843498-162@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843498)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity\nEstimated primary completion: 21 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/petrelintide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07843498
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07820358-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07820358)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Semaglutide\,
  Weight Loss\, and LNG-IUD for Conservative Treatment of Endometrial Atypi
 cal Hyperplasia and Grade 1 Endometrial Cancer\nEstimated primary completi
 on: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /semaglutide-wegovy#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07820358
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668401-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07668401)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 13: A Research S
 tudy Investigating How Well the Medicine Zenagamtide Helps People in Asia 
 With Excess Body Weight Lose Weight\nEstimated primary completion: 11 Janu
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 68401
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06383390-118@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:retatrutide: Phase 3 readout est. (NCT06383390)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: The Effect of Retatrut
 ide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults L
 iving With Obesity (TRIUMPH-Outcomes)\nEstimated primary completion: Febru
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retatrutide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063
 83390
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822061-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290205
DTEND;VALUE=DATE:20290206
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07822061)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 10: A Research S
 tudy Investigating How Well the Medicine NNC0487-0111 Helps People in Japa
 n With Excess Body Weight Lose Weight\nEstimated primary completion: 5 Feb
 ruary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamti
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7822061
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794774-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290221
DTEND;VALUE=DATE:20290222
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07794774)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Safety and Effects of Once-monthly Treatment With Berobenatide in Adults
  With Obesity Disease in Japan (VESPER-JM)\nEstimated primary completion: 
 21 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ber
 obenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07794774
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07078838-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07078838)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
  in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade
  1 Endometrial Cancer\nEstimated primary completion: March 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07078838
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07909889-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07909889)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Semaglutide f
 or Weight Management During Hormone Therapy for Early Breast Cancer\nEstim
 ated primary completion: March 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07909889
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806851-199@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:UBT251: Phase 3 readout est. (NCT07806851)
DESCRIPTION:UBT251\, phase 3\, Obesity.\nStudy: UBT251 Injection Phase Ⅲ 
 Study (OSA-PAP)\nEstimated primary completion: March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07806851
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794761-179@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290314
DTEND;VALUE=DATE:20290315
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07794761)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Safety and Effects of Once-weekly Treatment With Berobenatide in Adults 
 With Obesity Disease in Japan (VESPER-JW)\nEstimated primary completion: 1
 4 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beroben
 atide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07794761
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850063-119@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290429
DTEND;VALUE=DATE:20290430
SUMMARY:survodutide: Phase 3 readout est. (NCT07850063)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: ELEVATE-LIVER: A Study
  to Test Whether Survodutide Helps Improve Heart Structure and Function in
  People With Overweight or Obesity and Fatty Liver Disease\nEstimated prim
 ary completion: 29 April 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/survodutide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07850063
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946796-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07946796)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Semaglutide E
 ffects on Sperm Concentration in Overweight Infertile Men\nEstimated prima
 ry completion: June 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07946796
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339423-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290626
DTEND;VALUE=DATE:20290627
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07339423)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 1: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight Lose Weight\nEstimated primary completion: 26 June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07339423
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07781150-183@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:mazdutide: Phase 2 readout est. (NCT07781150)
DESCRIPTION:mazdutide\, phase 2\, Obesity.\nStudy: Mazdutide Plus LNG-IUS f
 or Fertility-Sparing Treatment of AEH or Early Endometrial Cancer\nEstimat
 ed primary completion: 30 June 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/mazdutide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07781150
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06582875-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06582875)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Glucagon-Li
 ke Peptide-1 Receptor Agonist in ADPKD\nEstimated primary completion: 30 J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide
 -zepbound#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06582875
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567001-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290723
DTEND;VALUE=DATE:20290724
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07567001)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study to Lo
 ok at How Well NNC0487-0111 Works Compared to Placebo in People With Heart
  Failure and Obesity\nEstimated primary completion: 23 July 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07567001
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794579-117@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07794579)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron in Participants With Overweight at Risk of Development of Ob
 esity-Related Complications or Progression to Class 1 Obesity\nEstimated p
 rimary completion: August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/orforglipron#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07794579
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517212-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06517212)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
  Weight Loss for MRD+ Early Breast Cancer\nEstimated primary completion: 3
 1 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzep
 atide-zepbound#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06517212
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881432-278@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:eloralintide: Phase 3 readout est. (NCT07881432)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of EloraTZP i
 n Adult Participants With Obesity Without Type 2 Diabetes\nEstimated prima
 ry completion: October 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/eloralintide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07881432
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881432-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07881432)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes\nEstim
 ated primary completion: October 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07881432
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881458-278@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:eloralintide: Phase 3 readout est. (NCT07881458)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of EloraTZP i
 n Adult Participants With Obesity or Overweight and Type 2 Diabetes\nEstim
 ated primary completion: October 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/eloralintide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07881458
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881458-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07881458)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabe
 tes\nEstimated primary completion: October 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07881458
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349641-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07349641)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: A Study of 
 Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Devic
 e to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer\nEstimat
 ed primary completion: 31 October 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07349641
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900633-278@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:eloralintide: Phase 3 readout est. (NCT07900633)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity or Overweight\, Type 2 Diabete
 s\, and Increased Cardiovascular Risk\nEstimated primary completion: Novem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eloralintid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 900633
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855900-119@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291106
DTEND;VALUE=DATE:20291107
SUMMARY:survodutide: Phase 3 readout est. (NCT07855900)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: SYNCHRONIZE®-START- A
  Study to Test Whether Survodutide Helps People Living With Overweight or 
 Obesity Who do Not Have Diabetes to Lose Weight\nEstimated primary complet
 ion: 6 November 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /survodutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07855900
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817875-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07817875)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Efficacy\, 
 Safety\, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versu
 s Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Hav
 e Obesity (ADVANCE-SURMOUNT-KIDS)\nEstimated primary completion: December 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zep
 bound#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07817875
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07693608-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300201
DTEND;VALUE=DATE:20300202
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07693608)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: An Open-Lab
 el Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder\nEsti
 mated primary completion: 1 February 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07693608
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253285-120@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300320
DTEND;VALUE=DATE:20300321
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07253285)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: A Research Study on H
 ow Well Cagrilintide and CagriSema Work in Children and Adolescents With E
 xcess Body Weight\nEstimated primary completion: 20 March 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07253285
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253285-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300320
DTEND;VALUE=DATE:20300321
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT07253285)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: A Research St
 udy on How Well Cagrilintide and CagriSema Work in Children and Adolescent
 s With Excess Body Weight\nEstimated primary completion: 20 March 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07253285
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134335-199@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300711
DTEND;VALUE=DATE:20300712
SUMMARY:UBT251: Phase 2 readout est. (NCT07134335)
DESCRIPTION:UBT251\, phase 2\, Obesity.\nStudy: UBT251 Injection Phase II C
 linical Study (CKD)\nEstimated primary completion: 11 July 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07134335
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843472-162@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300728
DTEND;VALUE=DATE:20300729
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843472)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity and Established Cardiovascular Disease\nEstimated primar
 y completion: 28 July 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/petrelintide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07843472
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790913-125@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Qsymia (phentermine/topiramate): Phase 2 readout est. (NCT07790913)
DESCRIPTION:Qsymia (phentermine/topiramate)\, phase 2\, Obesity.\nStudy: Ob
 esity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia a
 nd Lymphoma\nEstimated primary completion: August 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/phentermine-topiramate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07790913
URL:https://assetmemo.bio/drug/phentermine-topiramate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07861100-133@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300916
DTEND;VALUE=DATE:20300917
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07861100)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study to Lo
 ok at How Well Zenagamtide Works Compared to Placebo in People With Establ
 ished Atherosclerotic Cardiovascular Disease and Either Overweight or Obes
 ity\nEstimated primary completion: 16 September 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07861100
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06934655-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT06934655)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Early Reiniti
 ation of Semaglutide Post-Sleeve Gastrectomy in Youth\nEstimated primary c
 ompletion: 1 November 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06934655
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07731256-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07731256)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Semaglutide f
 or Low Back Pain\nEstimated primary completion: 1 January 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07731256
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845994-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT07845994)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: SEMAFORCRANIO
  : Multicenter\, Double-blind\, Parallel\, Randomized Controlled Trial of 
 the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopha
 ryngioma in Children Aged 12 to 17 Years\nEstimated primary completion: Ma
 rch 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide
 -wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07845994
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918846-159@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20310320
DTEND;VALUE=DATE:20310321
SUMMARY:enicepatide: Phase 3 readout est. (NCT07918846)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study Testi
 ng Enicepatide in Participants Living With Overweight or Obesity and Cardi
 ovascular Disease\nEstimated primary completion: 20 March 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07918846
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07021937-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT07021937)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Brain Plastic
 ity and GLP-1 Receptor Agonist Treatment for Obesity\nEstimated primary co
 mpletion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07021937
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949474-11054@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT07949474)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Semaglutide i
 n Alcohol Use Disorder\nEstimated primary completion: 30 April 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07949474
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874828-11052@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07874828)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: PROACT AYA:
  Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide 
 In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm\, Si
 ngle-Center Feasibility Study\nEstimated primary completion: 31 December 2
 034. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepb
 ound#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07874828
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
